gaboxadol has been researched along with Premenstrual Syndrome in 1 studies
gaboxadol: GABA agonist; inhibitor of GABA uptake systems; structure
Premenstrual Syndrome: A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gaboxadol (1." | 1.32 | Progesterone withdrawal increases the anxiolytic actions of gaboxadol: role of alpha4betadelta GABA(A) receptors. ( Gong, QH; Gulinello, M; Smith, SS, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gulinello, M | 1 |
| Gong, QH | 1 |
| Smith, SS | 1 |
1 other study available for gaboxadol and Premenstrual Syndrome
| Article | Year |
|---|---|
Progesterone withdrawal increases the anxiolytic actions of gaboxadol: role of alpha4betadelta GABA(A) receptors.
Topics: Animals; Anti-Anxiety Agents; Drug Implants; Female; GABA Agonists; Hippocampus; Ion Channels; Isoxa | 2003 |